Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration

[1]  R. Advani,et al.  Primary Mediastinal B cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium SocietyTM Appropriate Use Criteria. , 2021, International journal of radiation oncology, biology, physics.

[2]  A. Maity,et al.  Risk of pneumonitis and outcomes after mediastinal proton therapy for relapsed/refractory lymphoma: A PTCOG and PCG collaboration. , 2020, International journal of radiation oncology, biology, physics.

[3]  X. Zhu,et al.  Effect of Deep Inspiration Breath Hold on Normal Tissue Sparing With Intensity Modulated Radiation Therapy Versus Proton Therapy for Mediastinal Lymphoma , 2020, Advances in radiation oncology.

[4]  K. Herfarth,et al.  Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk , 2020, Frontiers in Oncology.

[5]  D. Scott,et al.  Outcome of Primary Mediastinal Large B-cell Lymphoma Using R-CHOP: Impact of a PET Adapted Approach. , 2020, Blood.

[6]  C. McCollough,et al.  Reducing Heart Dose with Protons and Cardiac Substructure Sparing for Mediastinal Lymphoma Treatment , 2020, International journal of particle therapy.

[7]  D. Chang,et al.  Second cancer risk after primary cancer treatment with three‐dimensional conformal, intensity‐modulated, or proton beam radiation therapy , 2020, Cancer.

[8]  C. Steidl,et al.  Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas , 2020, Haematologica.

[9]  R. Stewart,et al.  Comparative photon and proton dosimetry for patients with mediastinal lymphoma in the era of Monte Carlo treatment planning and variable relative biological effectiveness , 2019, Radiation Oncology.

[10]  K. Herfarth,et al.  Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison , 2019, Strahlentherapie und Onkologie.

[11]  R. Varadhan,et al.  R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma , 2019, Leukemia & lymphoma.

[12]  G. Follows,et al.  The management of primary mediastinal B‐cell lymphoma: a British Society for Haematology Good Practice Paper , 2019, British journal of haematology.

[13]  R. Mohan,et al.  Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. , 2018, Blood.

[14]  S. Engelholm,et al.  Comparative treatment planning study for mediastinal Hodgkin’s lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy , 2018, Acta oncologica.

[15]  W. Wilson,et al.  End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making , 2018, Haematologica.

[16]  Sonali M. Smith,et al.  Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R , 2017, British journal of haematology.

[17]  D. Cutter,et al.  Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. , 2017, International journal of radiation oncology, biology, physics.

[18]  Jian Cheng,et al.  The evolution of proton beam therapy: Current and future status. , 2017, Molecular and clinical oncology.

[19]  Wei Liu,et al.  Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee. , 2017, International journal of radiation oncology, biology, physics.

[20]  Zuofeng Li,et al.  Comparing Breath Hold and Free Breathing during Intensity-Modulated Radiation Therapy and Proton Therapy in Patients with Mediastinal Hodgkin Lymphoma. , 2017, International journal of particle therapy.

[21]  S. Flampouri,et al.  Pulmonary Toxicity Following Proton Therapy for Thoracic Lymphoma. , 2017, International journal of radiation oncology, biology, physics.

[22]  S. Hahn,et al.  Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment , 2016, Acta oncologica.

[23]  Frederik Wenz,et al.  Deep Inspiration Breath Hold-Based Radiation Therapy: A Clinical Review. , 2016, International journal of radiation oncology, biology, physics.

[24]  J. Byrd,et al.  Diffuse Large B-Cell Lymphoma Version 1.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  N. Tarbell,et al.  Secondary Malignancy Risk Following Proton Radiation Therapy , 2015, Front. Oncol..

[26]  Zuofeng Li,et al.  Proton therapy in the management of non-Hodgkin lymphoma , 2015, Leukemia & lymphoma.

[27]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Aznar,et al.  Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Shulian Wang,et al.  Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy , 2013, Leukemia & lymphoma.

[30]  S Dowdell,et al.  Interplay effects in proton scanning for lung: a 4D Monte Carlo study assessing the impact of tumor and beam delivery parameters , 2013, Physics in medicine and biology.

[31]  L. Staudt,et al.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. , 2013, The New England journal of medicine.

[32]  Zuofeng Li,et al.  Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study. , 2012, International journal of radiation oncology, biology, physics.

[33]  J. Buchsbaum,et al.  Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin's lymphoma in female pediatric patients. , 2011, International journal of radiation oncology, biology, physics.

[34]  J. Cox,et al.  Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. , 2011, International journal of radiation oncology, biology, physics.

[35]  A. Ho,et al.  Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Zuofeng Li,et al.  Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[37]  E Pedroni,et al.  Experimental characterization and physical modelling of the dose distribution of scanned proton pencil beams , 2005, Physics in medicine and biology.

[38]  J. Friedberg,et al.  Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Ling,et al.  Technical aspects of the deep inspiration breath-hold technique in the treatment of thoracic cancer. , 2000, International journal of radiation oncology, biology, physics.

[40]  M. Dimopoulos,et al.  PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy , 2016, Leukemia.

[41]  W. Wilson,et al.  Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? , 2015, Blood.

[42]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[43]  E. Yorke,et al.  Deep inspiration breath hold and respiratory gating strategies for reducing organ motion in radiation treatment. , 2004, Seminars in radiation oncology.